DETECTION OF OCCULT DISSEMINATED TUMOUR CELLS AND TUMOUR DNA IN EARLY STAGE OPERABLE BREAST CANCER PATIENTS

早期可手术乳腺癌患者隐匿性播散肿瘤细胞和肿瘤DNA的检测

• 批准号: nhmrc : 350452
• 负责人: A/Pr Alexander Dobrovic
• 金额: $ 37.41万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-01-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/detection-occult-disseminated-cancer-patients/76704
• 关键词: DETECTION; OCCULT; DISSEMINATED; TUMOUR; CELLS

Most of the reduction in breast cancer death rate in recent years is due to earlier diagnosis because of mammographic screening. Even among women with very favorable tumours, at least 20% will die of breast cancer. The risk increases to over 50% in less favorable cases of operable early breast cancer. Current practice relies very heavily upon prognostic factors such as lymph node status and tumour size in determining the risk of subsequent failure and the need for therapy. There is a significant risk of under treating good prognosis disease patients (20%) and over treating women with intermediate and high risk disease (40%). The first aim of the study is to use novel molecular methodologies to detect breast cancer cells in the blood of patients with early stage breast cancer at diagnosis. The presence of tumour cells will be correlated with the usual prognostic factors used in the management of women with breast cancer. The patients will be followed long-term to clarify the relationship between disseminated tumour cells in the blood and bone marrow and eventual outcome to assess the effectiveness of these new methodologies in patient management. We will also assess new molecular methodologies which will allow us to track very low levels of disease, and thereby monitor the effectiveness of treatment, and allow prediction of impending relapse. Studying the blood of breast cancer patients represents a unique opportunity for determining whether the cancer has spread before surgery and for monitoring of disease after surgical removal of the tumour. This study may prove invaluable in predicting disease free and survival outcomes and provide a more rational approach to the use of chemotherapy in patients with early breast cancer.

近年来乳腺癌死亡率的下降大部分是由于乳房X光检查的早期诊断。即使在肿瘤非常好的女性中，也至少有20%会死于乳腺癌。在不太有利的可手术早期乳腺癌病例中，风险增加到50%以上。目前的做法在很大程度上依赖于预后因素，如淋巴状态和肿瘤大小，以确定后续失败的风险和治疗的必要性。治疗预后良好的疾病患者不足(20%)和治疗中高风险疾病的妇女(40%)的风险很大。这项研究的第一个目的是使用新的分子方法来检测早期乳腺癌患者确诊时血液中的乳腺癌细胞。肿瘤细胞的存在将与乳腺癌妇女治疗中使用的常见预后因素相关。将对患者进行长期跟踪，以澄清血液和骨髓中播散的肿瘤细胞与最终结果之间的关系，以评估这些新方法在患者管理中的有效性。我们还将评估新的分子方法，这些方法将使我们能够跟踪非常低的疾病水平，从而监测治疗的有效性，并能够预测即将出现的复发。研究乳腺癌患者的血液是一个独特的机会，可以在手术前确定癌症是否已经扩散，并在手术切除肿瘤后监测疾病。这项研究可能被证明在预测无病和生存结果方面很有价值，并为早期乳腺癌患者使用化疗提供了一种更合理的方法。